Biomea Fusion, Inc. Financing Cash Flow
Biomea Fusion, Inc. (BMEA) reported Financing Cash Flow of $159.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- Biomea Fusion, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $23.11M, a 5496.13% increase year-over-year.
- Biomea Fusion, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.97M, a 2752.17% increase year-over-year.
- Biomea Fusion, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $39.57M, a 3598.32% increase year-over-year.
- Biomea Fusion, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $3.25M, a 2703.45% increase year-over-year.
- Biomea Fusion, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $67.90M, a 3970.98% increase from fiscal 2024.
- Biomea Fusion, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $1.67M, a 98.98% decline from fiscal 2023.
- Biomea Fusion, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $163.80M, a 13120.18% increase from fiscal 2022.
- Biomea Fusion, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $1.24M, a 99.19% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $159.00K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $23.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $25.08M derived: sum of 2 quarters · filed 2026-03-24 | $64.65M derived: sum of 3 quarters · filed 2026-08-05 | $67.90M 10-K · filed 2026-03-24 |
| 2025-09-30 | $1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $41.54M derived: sum of 2 quarters · filed 2026-08-05 | $44.79M 10-Q · filed 2025-11-04 | $45.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $39.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $42.82M 10-Q · filed 2026-08-05 | $43.24M derived: sum of 3 quarters · filed 2026-08-05 | $43.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.25M 10-Q · filed 2026-05-11 | $3.67M derived: sum of 2 quarters · filed 2026-05-11 | $3.73M derived: sum of 3 quarters · filed 2026-05-11 | $4.80M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $413.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $482.00K derived: sum of 2 quarters · filed 2026-03-24 | $1.55M derived: sum of 3 quarters · filed 2026-03-24 | $1.67M 10-K · filed 2026-03-24 |
| 2024-09-30 | $69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.14M derived: sum of 2 quarters · filed 2025-11-04 | $1.25M 10-Q · filed 2025-11-04 | $1.88M derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.19M 10-Q · filed 2025-08-05 | $1.81M derived: sum of 3 quarters · filed 2026-03-24 | $1.95M derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-03-31 | $116.00K 10-Q · filed 2025-05-05 | $738.00K derived: sum of 2 quarters · filed 2026-03-24 | $876.00K derived: sum of 3 quarters · filed 2026-03-24 | $163.71M derived: sum of 4 quarters · filed 2026-03-24 |
| 2023-12-31 | $622.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $760.00K derived: sum of 2 quarters · filed 2026-03-24 | $163.60M derived: sum of 3 quarters · filed 2026-03-24 | $163.80M 10-K · filed 2026-03-24 |
| 2023-09-30 | $138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $162.97M derived: sum of 2 quarters · filed 2024-10-29 | $163.18M 10-Q · filed 2024-10-29 | $163.67M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $162.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $163.04M 10-Q · filed 2024-07-31 | $163.53M derived: sum of 3 quarters · filed 2025-03-31 | $163.93M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $201.00K 10-Q · filed 2024-05-02 | $691.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.09M derived: sum of 3 quarters · filed 2025-03-31 | $1.41M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $490.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $890.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.21M derived: sum of 3 quarters · filed 2025-03-31 | $1.24M 10-K · filed 2025-03-31 |
| 2022-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $718.00K derived: sum of 2 quarters · filed 2023-10-30 | $749.00K 10-Q · filed 2023-10-30 | $995.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $318.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $349.00K 10-Q · filed 2023-07-31 | $595.00K derived: sum of 3 quarters · filed 2024-03-28 | $595.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $31.00K 10-Q · filed 2023-05-02 | $277.00K derived: sum of 2 quarters · filed 2024-03-28 | $277.00K derived: sum of 3 quarters · filed 2024-03-28 | $153.22M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $246.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $246.00K derived: sum of 2 quarters · filed 2024-03-28 | $153.19M derived: sum of 3 quarters · filed 2024-03-28 | $153.19M 10-K · filed 2024-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $152.94M derived: sum of 2 quarters · filed 2022-11-07 | $152.94M 10-Q · filed 2022-11-07 | $209.33M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $152.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $152.94M 10-Q · filed 2022-08-01 | $209.33M derived: sum of 3 quarters · filed 2023-03-28 | $209.33M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | -$3.00K 10-Q · filed 2022-05-16 | $56.38M derived: sum of 2 quarters · filed 2023-03-28 | $56.38M derived: sum of 3 quarters · filed 2023-03-28 | $65.91M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $56.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $56.39M derived: sum of 2 quarters · filed 2023-03-28 | $65.92M derived: sum of 3 quarters · filed 2023-03-28 | $65.97M 10-K · filed 2023-03-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $9.53M derived: sum of 2 quarters · filed 2021-11-03 | $9.58M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $9.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $9.58M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $50.00K 10-Q · filed 2021-05-27 | |||
| 2019-12-31 | $1.44M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |